NCT01889602View on ClinicalTrials.gov

Characterizing and Predicting Drug Effects on Cognition

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Cognitive Deficits
Interventions
DRUG

Lorazepam

Lorazepam: 2mg, po, 1x

OTHER

Placebo

Non-active placebo, po, 1x

DRUG

Topiramate 100mg

Topiramate: 100 mg, po, 1x

DRUG

Topiramate 150mg

Topiramate: 150 mg, po, 1x

DRUG

Topiramate 200mg

Topiramate: 200 mg, po, 1x

Trial Locations (1)

55414

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT01889602 - Characterizing and Predicting Drug Effects on Cognition | Biotech Hunter | Biotech Hunter